| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
|
| | Lapaquistat Basic information |
| Product Name: | Lapaquistat | | Synonyms: | T 91485;HDGUKVZPMPJBFK-LEAFIULHSA-N;4-Piperidineacetic acid, 1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-4,1-benzoxazepin-3-yl]acetyl]-;2-(1-(2-((3R,5S)-7-Chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydrobenzo[e][1,4]oxazepin-3-yl)acetyl)piperidin-4-yl)acetic acid;Lapaquistat (T-91485) | | CAS: | 189059-71-0 | | MF: | C31H39ClN2O8 | | MW: | 603.1 | | EINECS: | | | Product Categories: | | | Mol File: | 189059-71-0.mol |  |
| | Lapaquistat Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 25 mg/mL (41.45 mM) | | form | Solid | | color | White to off-white |
| | Lapaquistat Usage And Synthesis |
| Uses | Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy[1]. | | in vivo | After oral administration to rats, Lapaquistat Lapaquistat acetate (HY-16274) is absorbed and rapidly hydrolyzed into a pharmacological active metabolite, Lapaquistat[1]. | | References | [1] Nishimoto T, et al. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol. 2003 Dec 1;66(11):2133-9. DOI:10.1016/j.bcp.2003.08.011 |
| | Lapaquistat Preparation Products And Raw materials |
|